Back to discover
Drug

Inotersen sodium

Approved · EMA

Also known as Tegsedi, inotersen (as sodium).

RxNorm2099290
1
Regulatory events
Latest activity
beta

Recent clinical, regulatory, research and industry developments relating to this drug.

Profile

Identifiers & mechanism

Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.

Canonical name
Inotersen sodium
Aliases & brands
Tegsediinotersen (as sodium)
RxNorm CUI
2099290
Regulatory jurisdictions
ema

Regulatory timeline

1 event

The complete regulatory record, grouped by authority — approvals, safety advisories and label changes. Each authority shows its most recent events; expand one to read its full history.

Earliest approval
2018-07-06
Latest approval
2018-07-06
Authorities
EMA
Total events
1
emaEuropean Medicines Agency· 1 event
2018-07-06Accelerated approval
Accelerated approval: Tegsedi (EMA)

Indication: Treatment of stage 1 or Stage 2 polyneuropathy in adult patients with hereditary transthyretin amyloidosis (hATTR).

Evidence ↗

Contains information from the European Medicines Agency (European Medicines Agency), © EMA, reused under CC BY 4.0.

References & data sources
  • RxNorm (U.S. National Library of Medicine) — drug identity
  • Regulatory event sources are credited in the Regulatory Timeline above.